Telomir Pharmaceuticals (NASDAQ:TELO) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPS

Telomir Pharmaceuticals (NASDAQ:TELO) issued its quarterly earnings data on Friday. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.07, FiscalAI reports.

Telomir Pharmaceuticals Price Performance

NASDAQ TELO opened at $0.71 on Friday. The company’s fifty day simple moving average is $1.10 and its 200-day simple moving average is $1.21. Telomir Pharmaceuticals has a 52 week low of $0.69 and a 52 week high of $1.58.

Institutional Investors Weigh In On Telomir Pharmaceuticals

Large investors have recently bought and sold shares of the company. BlackRock Inc. purchased a new position in shares of Telomir Pharmaceuticals during the second quarter worth approximately $359,000. OneDigital Investment Advisors LLC acquired a new position in Telomir Pharmaceuticals in the 2nd quarter valued at approximately $29,000. Finally, Bank of New York Mellon Corp acquired a new position in Telomir Pharmaceuticals in the 2nd quarter valued at about $66,000.

Analysts Set New Price Targets

Several research firms recently commented on TELO. Weiss Ratings reiterated a “sell (e+)” rating on shares of Telomir Pharmaceuticals in a research note on Thursday, October 15th. Maxim Group initiated coverage on Telomir Pharmaceuticals in a research report on Thursday, September 17th. They issued a “buy” rating and a $4.00 price target on the stock. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $4.00.

Telomir Pharmaceuticals Company Profile

Telomir Pharmaceuticals, Inc is a development-stage biotechnology company focused on therapies intended to address age-related diseases and conditions. The company’s research is centered on telomere biology, a field involving the protective DNA sequences at the ends of chromosomes that are associated with cellular aging.

Telomir’s lead investigational product is TELOMIR-1, an orally administered small-molecule compound being developed to promote telomere lengthening and support cellular health.